A Placebo-controlled Double-blind Parallel-Group Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
Not Recruiting
50 years - 90 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this research is to find out if the study drug has a benefit on a person?s cognitive status via a series of specialized cognitive tests. The purpose of this research is also to find out if this study drug is safe and well-tolerated in people with early Alzheimer?s disease.
Detailed description of study
The purpose of this research is to find out if the study drug has a benefit on a person?s cognitive status via a series of specialized cognitive tests. The purpose of this research is also to find out if this study drug is safe and well-tolerated in people with early Alzheimer?s disease.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alzheimer's disease
-
Age: 50 years - 90 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1212010226
